GLMD (Galmed Pharmaceuticals) קצב צמיחת רווח למניה בשנה הנוכחית

סמלים רשמיים של חברת galmedpharma.com (GLMD)

The financial stability of Galmed Pharmaceuticals (GLMD) relies on the non-cyclical nature of biotech development, where cash is more critical than GDP. The YoY EPS dynamics on the GURU.Markets chart confirm this, while the 40.00 level captures the current state. The company is actively developing the drug Aramchol; however, geopolitical disruptions and sanctions are significantly hindering global certification and the conduct of international clinical trials.

GLMD (Galmed Pharmaceuticals Ltd) היסטוריית צמיחת רווחים בשנה הנוכחית מ-04.07.2022 עד 10.09.2026

פילוחים אנליטיים ודוחות נתונים של חברת Galmed Pharmaceuticals Ltd (GLMD)

ניתוח בסיסי של החברה:GLMD, Galmed Pharmaceuticals
מוצר המיוצר על ידי Galmed Pharmaceuticals Ltd.

This metric is calculated as the percentage deviation of current earnings per share from the value of the same period last year, measuring the efficiency rates of net income generation. This metric allows for an assessment of the issuer's fundamental stability through the dynamics of profit capitalization. For Galmed Pharmaceuticals (GLMD), during a period of organic asset development and pipeline revision, the current level of EPS YoY change reflects the actual productivity of targeted collaborations.